Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiotherapy dose and fractionation for stage III NSCLC.
Belderbos J, Walraven I, van Diessen J, Verheij M, de Ruysscher D. Belderbos J, et al. Among authors: walraven i. Lancet Oncol. 2015 Apr;16(4):e156-7. doi: 10.1016/S1470-2045(15)70121-X. Lancet Oncol. 2015. PMID: 25846093 No abstract available.
Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab.
Walraven I, van den Heuvel M, van Diessen J, Schaake E, Uyterlinde W, Aerts J, Koppe F, Codrington H, Kunst P, Dieleman E, van de Vaart P, Verheij M, Belderbos J. Walraven I, et al. Radiother Oncol. 2016 Mar;118(3):442-6. doi: 10.1016/j.radonc.2016.02.011. Epub 2016 Feb 15. Radiother Oncol. 2016. PMID: 26900091 Clinical Trial.
Adverse event development in clinical oncology trials.
Walraven I, Aaronson N, Sonke JJ, Verheij M, Belderbos J. Walraven I, et al. Lancet Oncol. 2016 Jul;17(7):e263. doi: 10.1016/S1470-2045(16)30197-8. Lancet Oncol. 2016. PMID: 27396639 No abstract available.
In Regard to Redmond et al.
Belderbos J, Schagen S, Walraven I, Deprez S, de Ruiter M, De Ruysscher D, Le Pechoux C. Belderbos J, et al. Among authors: walraven i. Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):238-239. doi: 10.1016/j.ijrobp.2017.05.012. Epub 2017 Aug 7. Int J Radiat Oncol Biol Phys. 2017. PMID: 28816152 No abstract available.
Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial.
Monninkhof EM, van Loon JWL, van Vulpen M, Kerkmeijer LGW, Pos FJ, Haustermans K, van den Bergh L, Isebaert S, McColl GM, Smeenk RJ, Noteboom J, Walraven I, Peeters PHM, van der Heide UA. Monninkhof EM, et al. Among authors: walraven i. Radiother Oncol. 2018 Apr;127(1):74-80. doi: 10.1016/j.radonc.2017.12.022. Epub 2018 Jan 11. Radiother Oncol. 2018. PMID: 29336835 Free article. Clinical Trial.
Quantitative 3-T multi-parametric MRI and step-section pathology of recurrent prostate cancer patients after radiation therapy.
Dinis Fernandes C, Ghobadi G, van der Poel HG, de Jong J, Heijmink SWTPJ, Schoots I, Walraven I, van Houdt PJ, Smolic M, Pos FJ, van der Heide UA. Dinis Fernandes C, et al. Among authors: walraven i. Eur Radiol. 2019 Aug;29(8):4160-4168. doi: 10.1007/s00330-018-5819-y. Epub 2018 Nov 12. Eur Radiol. 2019. PMID: 30421016 Free PMC article.
67 results